Singapore markets closed

DiaMedica Therapeutics Inc. (DMAC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.8600-0.4100 (-18.06%)
At close: 04:00PM EDT
1.9600 +0.10 (+5.38%)
After hours: 07:39PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.2700
Open2.3100
Bid1.9100 x 4000
Ask1.9100 x 1800
Day's range1.6200 - 2.3125
52-week range1.6200 - 7.3400
Volume294,575
Avg. volume47,158
Market cap49.184M
Beta (5Y monthly)2.34
PE ratio (TTM)N/A
EPS (TTM)-0.5940
Earnings date09 Aug 2022 - 15 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.80
  • Business Wire

    DiaMedica Therapeutics to Attend the 19th Annual Craig-Hallum Institutional Investor Conference Wednesday, June 1, 2022

    MINNEAPOLIS, May 25, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that it will be participating in the 19th Annual Craig-Hallum Institutional Investor Conference being held virtually on Wednesday, June 1, 2022. Management will be available to participate in one-on-one meetings. Investors and attendees that would like to schedule a meeting with Dia

  • Business Wire

    DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2022 Financial Results

    MINNEAPOLIS, May 04, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and released financial results for the quarter ended March 31, 2022. DiaMedica will host a conference call on Thursday, May 5, 2022, at 8:00AM Eastern Time / 7:00AM Central Time, to discuss its business update and first quarter financial results.

  • Business Wire

    DiaMedica Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update May 5, 2022

    MINNEAPOLIS, April 28, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its first quarter 2022 financial results will be released after the markets close on Wednesday, May 4th. DiaMedica will host a live conference call on Thursday, May 5th at 7:00 AM Central Time to provide a business update and discuss financial results.